Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Link between malaria and salmonella infections

Link between malaria and salmonella infections

Patients need less blood after surgery than is widely thought

Patients need less blood after surgery than is widely thought

Evidence-based interventions to reduce newborn and maternal mortality

Evidence-based interventions to reduce newborn and maternal mortality

Researchers identify second oldest human disease mutation

Researchers identify second oldest human disease mutation

More than half of older patients with anemia do not need transfusions after hip surgery

More than half of older patients with anemia do not need transfusions after hip surgery

Simple online calculator can tackle pancreatic and bowel cancer

Simple online calculator can tackle pancreatic and bowel cancer

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Researchers discover how bloodstream malaria infection manipulates immune system

Researchers discover how bloodstream malaria infection manipulates immune system

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

Combination of bortezomib and panobinostat shows promise against advanced MM

Combination of bortezomib and panobinostat shows promise against advanced MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Celgene announces results from azacitidine Phase 1 study on AML

Celgene announces results from azacitidine Phase 1 study on AML

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Breast cancer hope with new drug and new combination regimens

Breast cancer hope with new drug and new combination regimens

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.